welcome

Be part of advancing the treatment of Vascular Ehlers-Danlos Syndrome or VEDS with this exciting new study!

Acer Therapeutics is conducting a clinical trial in the U.S. to evaluate the efficacy and safety of an investigational drug known as celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).

Acer Therapeutics is actively seeking potential participants with a confirmed diagnosis of Vascular Ehlers-Danlos Syndrome (VEDS) patients caused by a COL3A1 mutation who are interested in participating in this investigational trial.
Celiprolol is an investigational drug and therefore its safety and efficacy have not been established. There is no guarantee that celiprolol will receive health authority approval or become commercially available for treatment of Vascular Ehlers-Danlos Syndrome (VEDS).